Compare FedEx Corporation (FDX) vs Pfizer Inc (PFE) Price & Performance

FedEx (FDX) trades at $318.57, up 0.85% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with a P/E of 17.17 and net income margin of 4.68%, supported by recent earnings beats. Network transformation initiatives and premium revenue mix are driving operational improvements, while analyst consensus remains strongly positive with a $360.27 price target.

Outlook remains favorable with projected revenue growth to $94.7B in 2026 and continued margin expansion. Key risks include competitive pressures in logistics and macroeconomic sensitivity. The stock offers value with reasonable valuation metrics and strong institutional support, though investors should monitor execution of cost-saving initiatives and freight demand trends.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.